Leader in research and rated high-performing in colon cancer surgery.
An international clinical trial involving UC Davis Health suggests the investigational drug Elafibranor is a potential novel treatment for patients with primary biliary cholangitis. Results showed significant improvements in biomarkers of disease progression. The results of the clinical trial were published in The New England Journal of Medicine. They were also presented by Christopher Bowlus, M.D., chief of Gastroenterology and Hepatology at UC Davis Health at The Liver Meeting, hosted by the American Association for the Study of Liver Disease.
Interventional gastroenterologists at UC Davis Health are offering new endoscopic procedures in the new leading-edge outpatient endoscopy suite. Some of the procedures provided include endoscopic treatment for Achalasia, characterization of pancreatic cysts using real time laser microscopy, and removal of early-stage tumors, among many others. The procedures are visually aided with advanced integrated fluoroscopy suites, 3-D mobile C-arm system, and more.
UC Davis Health researchers have infused their first Wilson Disease patient with gene therapy as part of a groundbreaking new clinical trial. The treatment has the potential to address the underlying cause of the disease. The industry-funded clinical trial with Ultragenyx is evaluating UX701, an investigational adeno-associated virus (AAV) vector-based gene therapy. UC Davis Health is one of just seven health care institutions worldwide to infuse a patient with this new gene therapy.
Mohamed R. Ali, M.D., chief of Foregut, Metabolic and General Surgery, performed the first robotic procedure at UC Davis Health.Learn more
Christopher Bowlus, M.D., is the lead author of national guidelines for managing primary sclerosing cholangitis and cholangiocarcinoma.Learn more
A U.S. News & World Report best hospital in cancer, cardiology, heart & vascular surgery, diabetes & endocrinology, ENT, geriatrics, neurology & neurosurgery, obstetrics & gynecology, and pulmonology & lung surgery.
U.S. News & World Report rated UC Davis Medical Center high performing in colon cancer surgery.
One of ~52 U.S. cancer centers designated “comprehensive” by the National Cancer Institute.
UC Davis Medical Center received Healthgrades® America’s 100 Best Hospitals Award for 2024, placing us among the top 2% of hospitals nationwide for overall clinical performance. We also received accolades for high-quality patient care, known as Specialty Excellent Awards, in five areas including cardiac, neurosciences, gastrointestinal, critical care and pulmonary specialties.
UC Davis Medical Center has been recognized as one of the nation’s top hospitals by the 2023 edition of Becker’s Hospital Review’s “Great hospitals in America” list.
UC Davis Medical Center has received Magnet® recognition, the nation’s highest honor for nursing excellence.
Ranked Sacramento’s #1 hospital by U.S. News, and high-performing in COPD, colon cancer surgery, diabetes, heart attack, heart failure, hip fracture, hip replacement, kidney failure, leukemia, lymphoma & myeloma, lung cancer surgery, ovarian cancer surgery, pneumonia, prostate cancer surgery, stroke, TAVR, uterine cancer surgery, gastroenterology & GI surgery, and orthopedics.